Literature DB >> 3508566

Effect of hydralazine on the elimination of antipyrine in the rat.

C K Svensson1, P W Knowlton, J A Ware.   

Abstract

The concomitant administration of hydralazine with metoprolol or propranolol substantially increases the oral bioavailability of these beta-blockers, presumably via reduction of the first-pass effect. It has been suggested that this effect may be secondary to a decrease in the intrinsic clearance of propranolol, possibly by inhibition of oxidative metabolism. To examine the possibility that hydralazine alters oxidative metabolism in vivo, the effect of hydralazine on the pharmacokinetics of antipyrine was examined in the rat. The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05). Hydralazine was observed to cause substantial hypothermia. The study was repeated in temperature-regulated animals and no alteration in antipyrine clearance was found. Two doses of hydralazine in temperature-regulated rats also failed to alter antipyrine clearance. Thus, it appears that the effect of hydralazine on antipyrine clearance is secondary to the hypothermic effect of hydralazine and not due to a direct inhibition of cytochrome P-450-mediated enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508566     DOI: 10.1023/a:1016487824200

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  CHRONIC INTRAVENOUS CANNULAS FOR RATS.

Authors:  J R WEEKS; J D DAVIS
Journal:  J Appl Physiol       Date:  1964-05       Impact factor: 3.531

3.  PROLONGATION OF HEXOBARBITAL SLEEPING TIME AND INHIBITION OF HEPATIC DRUG METABOLISM BY ADRENERGIC BLOCKING AGENTS IN MICE.

Authors:  J O MULLEN; J R FOUTS
Journal:  Biochem Pharmacol       Date:  1965-03       Impact factor: 5.858

4.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

5.  Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation.

Authors:  H Liedholm; A Melander
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

6.  Effect of food on hepatic blood flow: implications in the "food effect" phenomenon.

Authors:  C K Svensson; D J Edwards; P M Mauriello; S H Barde; A C Foster; R A Lanc; E Middleton; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

7.  Interaction between oral propranolol and hydralazine.

Authors:  A J McLean; H Skews; A Bobik; F J Dudley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

8.  Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.

Authors:  A J Byrne; J J McNeil; P M Harrison; W Louis; A M Tonkin; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

9.  Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil.

Authors:  R G McAllister; T G Tan
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

10.  Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow.

Authors:  C K Svensson; J C Cumella; M Tronolone; E Middleton; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

View more
  1 in total

1.  Traditional reactive carbonyl scavengers do not prevent the carbonylation of brain proteins induced by acute glutathione depletion.

Authors:  J Zheng; O A Bizzozero
Journal:  Free Radic Res       Date:  2010-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.